Jean-Jacques Bienaime Net Worth

The estimated Net Worth of Jean Jacques Bienaime is at least $48.5 Million dollars as of 15 August 2024. Mr. Bienaime owns over 7,000 units of Biomarin Pharmaceutical stock worth over $1,408,620 and over the last 20 years he sold BMRN stock worth over $28,715,384. In addition, he makes $18,405,900 as Chairman of the Board and Chief Executive Officer at Biomarin Pharmaceutical.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Bienaime BMRN stock SEC Form 4 insiders trading

Jean has made over 330 trades of the Biomarin Pharmaceutical stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of BMRN stock worth $97,580 on 15 August 2024.

The largest trade he's ever made was exercising 140,000 units of Biomarin Pharmaceutical stock on 7 November 2016 worth over $3,011,400. On average, Jean trades about 8,287 units every 16 days since 2005. As of 15 August 2024 he still owns at least 16,615 units of Biomarin Pharmaceutical stock.

You can see the complete history of Mr. Bienaime stock trades at the bottom of the page.

Jean-Jacques Bienaime biography

Jean-Jacques Bienaime serves as Chairman of the Board, Chief Executive Officer of Biomarin Pharmaceutical Inc., He joined our Board in May 2005, at the same time that he became our Chief Executive Officer, and was named Chair of the Board in June 2015. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé currently serves on the board of Incyte Corporation, a public biotechnology company, as well as being a member of the boards of Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA), both industry trade associations. Mr. Bienaimé previously served on the boards of three public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, InterMune, Inc., from 2012 to 2014, and Vital Therapies, Inc., from 2013 to 2018. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

What is the salary of Jean Bienaime?

As the Chairman of the Board and Chief Executive Officer of Biomarin Pharmaceutical, the total compensation of Jean Bienaime at Biomarin Pharmaceutical is $18,405,900. There are no executives at Biomarin Pharmaceutical getting paid more.

How old is Jean Bienaime?

Jean Bienaime is 65, he's been the Chairman of the Board and Chief Executive Officer of Biomarin Pharmaceutical since 2015. There are 7 older and 14 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.

What's Jean Bienaime's mailing address?

Jean's mailing address filed with the SEC is C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011.

Insiders trading at Biomarin Pharmaceutical

Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy, and Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.

What does Biomarin Pharmaceutical do?

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment

Complete history of Mr. Bienaime stock trades at Biomarin Pharmaceutical, Incyte, Portola Pharmaceuticals, Keros Therapeutics, and Immunome

Biomarin Pharmaceutical executives and stock owners

Biomarin Pharmaceutical executives and other stock owners filed with the SEC include:

• Jean-Jacques Bienaime,
  Chairman of the Board, Chief Executive Officer
• Henry Fuchs,
  President - Worldwide Research & Development
• Jeff Ajer,
  Executive Vice President, Chief Commercial Officer
• Jean-Jacques Bienaime M.B.A., MBA,
  Chairman & CEO
• G. Eric Davis,
  Executive Vice President, General Counsel, Secretary
• Dr. Henry J. Fuchs,
  Pres of Worldwide R&D
• Dr. C. Greg Guyer Ph.D.,
  CTO and Exec. VP of Global Manufacturing & Technical Operations
• Jeffrey Robert Ajer,
  Exec. VP & Chief Commercial Officer
• Brian R. Mueller,
  Exec. VP of Fin. & CFO
• Richard Meier,
  Lead Independent Director
• Elaine Heron,
  Independent Director
• Robert Hombach,
  Independent Director
• Alan Lewis,
  Independent Director
• Michael Grey,
  Independent Director
• V. Bryan Lawlis,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Slamon,
  Independent Director
• Willard Dere,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Lon Cardon,
  Chief Scientific Strategy Officer
• Andrea Acosta,
  Chief Accounting Officer, Group Vice President
• C. Greg Guyer,
  Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations
• Brian Mueller,
  Chief Financial Officer, Executive Vice President
• Dr. Brinda Balakrishnan M.D., Ph.D.,
  Group VP of Corp. & Bus. Devel.
• Philip Lo Scalzo,
  Sr. VP & Chief Compliance Officer
• George Eric Davis,
  Exec. VP, Gen. Counsel & Sec.
• Traci McCarty,
  VP of Investor Relations
• Andrea L. Acosta,
  Group VP & Chief Accounting Officer
• Daniel K Spiegelman,
  EVP, Chief Financial Officer
• Athena Countouriotis,
  Director
• Mark J Enyedy,
  Director
• Barbara W. Bodem,
  Director
• Robert Baffi,
  President, Global Mfg/Tech Ops
• Cristin Hubbard,
  EVP, Chief Commercial Officer
• Kathryn E Falberg,
  Director
• William D Young,
  Director
• Pierre Lapalme,
  Director
• Jeffrey Landau,
  Sr. Vice President, Admin.
• Gwynn Williams,
  Director
• Steve Aselage,
  SVP, Global Commercial Ops
• Christopher M Starr,
  Sr. VP, Scientific Operations
• Franz L Cristiani,
  Director
• Jeffrey H Cooper,
  Chief Financial Officer
• Joseph Iii Klein,
  Director
• Emil D Kakkis,
  SVP, Business Operations
• Kenneth Bate,
  Director
• Mark Wood,
  VP, Human Resources
• John Urquhart,
  Director
• Erich Sager,
  Director
• Stuart J Swiedler,
  SVP, Clinical Affairs
• Fredric D Price,
  Chief Executive Officer
• Vijay B Samant,
  Director
• Maykin Ho,
  Director
• Mark J Alles,
  Director
• Erin Burkhart,
  GVP, Chief Accounting Officer
• Alexander Hardy,
  Chief Executive Officer